Clinical trial
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in…
NCT00363649 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00363649 |
|---|---|
| Title | Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI |
| Official title | A Randomized Phase II Trial of Interferon + GM-CSF Versus K562/GM-CSF Vaccination in CML Patients Achieving a Complete Cytogenetic Response to Frontline Tyrosine Kinase Inhibitor Therapy |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | GM-K562 cell vaccine, Interferon alfa, Sargramostim |
| Enrollment | 36 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2017 |
| Completion | Sep 1, 2017 |
| First posted | Aug 15, 2006 |
| Last update posted | Nov 13, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: